Multiple Myeloma

Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.

Natalie S. Callander, MD, discusses the intriguing approaches in both the frontline and relapsed/refractory settings, including trials with antibody-drug conjugates.

Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.

Ajay K. Nooka, MD, MPH, FACP, discusses the utility of BCMA as a target in multiple myeloma.

Timothy M. Schmidt, MD, discusses the safety and efficacy of teclistamab in patients with multiple myeloma.

Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses single-agent and combination strategies that have recently been introduced to the relapsed/refractory multiple myeloma setting and the nuances to utilizing them in clinical practice.

Yi Lin, MD, PhD, discusses promising data with CAR T-cell therapy in multiple myeloma.

Rafael Fonseca, MD, discusses several clinical trials that support the use of quadruplet regimens in myeloma, the utilization of MRD in clinical decision-making, and future directions for research.

Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses the efficacy of combination carfilzomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.

Binod Dhakal, MD, discusses responses achieved with orvacabtagene autoleucel in patients with multiple myeloma.

Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.

Anita D’Souza, MD, discusses the utilization of monoclonal antibodies and immunomodulating agents in patients with light chain amyloidosis.

Sikander Ailawadhi, MD, discusses the future of relapsed/refractory multiple myeloma, the potential for retreatment with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, and the promise of T-cell engagers in the field.

Anita D’Souza, MD, discusses forming a treatment strategy for patients with relapsed light chain amyloidosis.

Shaji K. Kumar, MD, discusses novel combinations that are being introduced to the relapsed/refractory setting in multiple myeloma, the value of minimal residual disease, and the importance of understanding potential toxicity when utilizing newer agents in the space.

Timothy M. Schmidt, MD, discusses the clinical implications of AMG 420 in multiple myeloma.

Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.

February 4, 2021 — The Israeli Ministry of Health has approved selinexor for the treatment of patients with multiple myeloma or diffuse large B-cell lymphoma.

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Binod Dhakal, MD, discusses the differences in onset of cytokine release syndrome with CAR T-cell therapies in multiple myeloma.

Marc J. Braunstein, MD, PhD, discusses the current landscape of newly diagnosed multiple myeloma and the utility of minimal residual disease in the research sphere.